Vascular endothelial cells and angiogenesis

Area of Science:

• Molecular Biology
• Oncology
• Cell Biology

Background:

• Vascular endothelial cell division is normally limited, but angiogenesis (new blood vessel formation) is essential for tumor growth beyond 1 mm due to oxygen and nutrient needs.
• Tumor angiogenesis involves mature endothelial cells replicating and forming new capillaries, often driven by increased production of vascular endothelial growth factors (VEGFs).

Purpose of the Study:

• To explore the molecular mechanisms regulating angiogenesis, focusing on key signaling pathways and their components.
• To highlight the therapeutic potential of inhibiting angiogenic signaling in cancer treatment.

Main Methods:

• Review of literature on angiogenesis, including the roles of VEGF family, semaphorins, angiopoietins, ephrins, and other growth factors and their receptors.
• Identification of FDA-approved drugs targeting angiogenesis pathways.

Main Results:

• The VEGF family (VEGF-A/B/C/D, PlGF) and their receptors (VEGFR1/2/3, neuropilins) are central to angiogenesis.
• Semaphorins, angiopoietins, ephrins, and various growth factors (PDGF, FGF, HGF, SCF) also play significant roles through their respective receptors.
• Ponatinib, regorafenib, and vandetanib are approved inhibitors of VEGFR, Tie2, and Ephrin receptors, demonstrating clinical efficacy in malignancies.

Conclusions:

• Aberrant angiogenesis is implicated in tumor progression and diseases like diabetic retinopathy and age-related macular degeneration.
• Inhibition of angiogenic signaling pathways represents a viable and attractive therapeutic strategy for various cancers and other angiogenesis-dependent disorders.